Skip to main content

HBM Healthcare Investments AG (0QOC.L)

London Stock Exchange Financial Services Financial - DiversifiedView data quality →
49.6Fair

ValueMarkers Composite Index

Top 27%#32,601 of 44,714
Undervalued

903% below intrinsic value ($26)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
2.17
High Risk
Altman
10.16
Safe
DCF Value
$26
Overvalued
ROIC
11.7%
Adequate
P/E
6.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

HBM Healthcare Investments AG (0QOC.L) — VMCI valuation read

Headline read on 0QOC.L: VMCI of 50/100 versus a Financial Services sector median of 50. The 0-point below-median position is what makes HBM Healthcare Investments AG a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 0QOC.L: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 0QOC.L: value (0QOC.L trades at 27.0x earnings, 50% above the Financial Services median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Financial Services median (10.0%)), and risk (net debt to EBITDA of 0.2x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Financial Services 12.0x baseline.

0QOC.L rose 2.1% over the trailing 7 days, with a -13.0% read on a 30-day basis.

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.

CEO: Andreas WickiCHwww.hbmhealthcare.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0QOC.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.